Leonardo DRS, Inc. Common Stock (DRS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Leonardo DRS, Inc. Common Stock.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 46.10 $ — 79% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 10.6% failed
- More than 10% revenue growth is expected for the coming year 6.7% failed
- Share count grows by less than 3% a year 7.7% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 19.0% failed
- Gross margin at 40% or higher and without meaningful erosion 23.2% failed
- Goodwill from acquisitions does not grow faster than revenue 26.8% passed
- Net debt below twice EBITDA 177 m net cash passed
- Operating cash flow covers the profits of the last three years 183 m passed
- Return on capital at 15% or higher, or up versus two years ago 10.3% passed
- Insiders hold at least 10% or are net buyers 71.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 16.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.38 | 1.34 – 1.40 | 3,944 | 20.4% | 7 |
| 12/31/2027 | 1.47 | 1.38 – 1.57 | 4,211 | 5.9% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.33 | 19.20 | 981 | 5.90 | 9.10 | 443 | 414 |
| 2025: Q1 | 0.19 | 70.90 | 799 | 16.10 | 6.30 | -138 | -170 |
| 2025: Q2 | 0.20 | 41.20 | 829 | 10.10 | 6.50 | -28 | -56 |
| 2025: Q3 | 0.27 | 25.90 | 960 | 18.20 | 7.50 | 107 | 77 |
| 2025: Q4 | 0.38 | 14.30 | 1,060 | 8.10 | 9.60 | 425 | 376 |
| 2026: Q1 | 0.23 | 24.00 | 846 | 5.90 | 7.30 | -66 | -96 |
| 2026: Q2 | 0.32 | 60.00 | 913 | 10.10 | 9.40 | 35 | 6 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 13 | -3 | -5 | -0.23 | -5 | 11 | 21 |
| 2017 | 26 | 2 | 2 | 0.07 | 1 | 29 | 36 |
| 2018 | 2,333 | 45 | -10 | -0.07 | 105 | 42 | 54 |
| 2019 | 2,714 | 163 | 75 | 0.52 | 157 | 1,019 | 2,888 |
| 2020 | 2,778 | 181 | 85 | 0.57 | 125 | 1,427 | 2,956 |
| 2021 | 2,879 | 236 | 154 | 1.06 | 178 | 1,593 | 3,069 |
| 2022 | 2,693 | 561 | 405 | 1.88 | 33 | 2,127 | 3,677 |
| 2023 | 2,826 | 231 | 168 | 0.64 | 205 | 2,325 | 3,921 |
| 2024 | 3,234 | 293 | 213 | 0.80 | 271 | 2,557 | 4,184 |
| 2025 | 3,648 | 348 | 278 | 1.03 | 366 | 2,730 | 4,617 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Leonardo DRS, Inc. bietet gemeinsam mit ihren Tochtergesellschaften weltweit Verteidigungselektronikprodukte und -systeme sowie militärische Unterstützungsdienste an.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 7,300 |
| Headquarters | Arlington, VA |
| Address | 2345 Crystal Drive, 22202 Arlington, United States |
| Phone | 703 416 8000 |
| Website | leonardodrs.com |
| IPO Date | 29. Nov 2022 |
| ISIN | US52661A1088 |
| Stock Split | 1:2 on 09/14/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John A. Baylouny | President, CEO & Director | 1961 |
| Michael D. Dippold | Executive VP & CFO | 1981 |
| Sally A. Wallace | Executive VP & COO | 1967 |
| Mark A. Dorfman J.D. | Executive VP, General Counsel & Secretary | 1974 |
| Philip Perconti | Senior VP & CTO | – |
| Stephen Vather | Senior VP of Corporate Development (M&A) & Investor Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 7. Jul 2026 | Rinsky Jason | EVP Chief Tax and Treasury | Sell | 3,865 | 45.37 | 175,355 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.